In recent years, glucagon-like peptide 1 (GLP-1) receptor have gained considerable attention as a target for the clinical treatment of metabolic disorders, particularly of type 2 diabetes (T2D) and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.